Isotretinoin
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Severe recalcitrant nodular acne unresponsive to conventional therapy including systemic antibiotics | ≥12 years (non-pregnant) | Monotherapy (systemic) | FDA Approved |
Isotretinoin received FDA approval in 1982 for severe recalcitrant nodular acne characterized by multiple inflammatory nodules ≥5 mm in diameter that have failed adequate courses of standard therapy, including oral antibiotics. In clinical practice, the AAD guidelines also recommend isotretinoin for patients with moderate-to-severe acne causing significant scarring or psychosocial burden, even without classical nodular disease. It remains the only acne treatment capable of producing long-term remission in the majority of patients, with up to 70% achieving sustained clearance after a single course.
Rosacea (severe/refractory) — Evidence quality: Moderate. Low-dose isotretinoin (0.25–0.5 mg/kg/day) has demonstrated benefit in papulopustular rosacea resistant to standard therapies.
Hidradenitis suppurativa — Evidence quality: Low. Some evidence for mild-to-moderate disease, though efficacy is inferior to biologics for severe disease.
Harlequin ichthyosis and lamellar ichthyosis — Evidence quality: Moderate. Used as chronic suppressive therapy in severe congenital ichthyoses.
Seborrheic dermatitis (severe) — Evidence quality: Low. Reduces sebum production; limited controlled data.
Folliculitis decalvans — Evidence quality: Low. Case series report benefit in refractory cases.
Dosing
Standard Dosing (≥12 years, non-pregnant)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Severe nodular acne — standard-weight patient | 0.5 mg/kg/day in 1–2 divided doses | 1.0 mg/kg/day in 2 divided doses | 2.0 mg/kg/day | Increase after 4 weeks if tolerated; take with food (high-fat meal preferred) Target cumulative dose: 120–150 mg/kg over 15–20 weeks |
| Severe scarring acne with trunk involvement | 0.5 mg/kg/day | 1.0–2.0 mg/kg/day in divided doses | 2.0 mg/kg/day | Higher cumulative doses may be needed for extensive trunk disease Some clinicians target ≥150 mg/kg cumulative to reduce relapse risk |
| Moderate acne with psychosocial impact or scarring risk | 0.25–0.5 mg/kg/day | 0.5–1.0 mg/kg/day | 1.0 mg/kg/day | Lower starting dose reduces risk of acne flare Off-label use guided by AAD recommendations |
| Re-treatment after relapse | 0.5 mg/kg/day | 1.0 mg/kg/day | 2.0 mg/kg/day | Wait ≥8 weeks after completing first course before retreating Patients may continue improving after stopping; re-evaluate before restarting |
| Dose reduction for intolerance (mucocutaneous AEs) | Reduce to previously tolerated dose | N/A | Extend duration to reach cumulative target; lower daily doses reduce side effects while maintaining efficacy Some patients require treatment beyond 20 weeks at lower doses | |
The cumulative dose of 120–150 mg/kg is the strongest predictor of sustained remission. Courses that reach this target have significantly lower relapse rates than those that do not. Data suggest 44% of patients treated beyond 5 months, and clinicians should prioritize reaching the cumulative target even if this means extending treatment duration at a tolerable daily dose. The FDA-approved dosing frequency is twice daily with food, though many clinicians prescribe once-daily dosing to improve adherence.
Pharmacology
Mechanism of Action
Isotretinoin (13-cis-retinoic acid) is a naturally occurring vitamin A metabolite that exerts its therapeutic effects primarily through marked reduction in sebaceous gland size and sebum output — the only known medication to produce this effect at a level sufficient for long-term acne remission. The drug itself has low affinity for retinoic acid receptors (RAR) and retinoid X receptors (RXR), but it is converted intracellularly to metabolites including all-trans-retinoic acid (tretinoin) and 4-oxo-isotretinoin, which act as agonists at nuclear RAR and RXR receptors to modulate gene transcription.
The clinical effects of isotretinoin are multifactorial. It induces apoptosis in sebocytes, shrinking sebaceous glands by up to 90% and reducing sebum production to negligible levels. It normalizes follicular keratinization, preventing the formation of microcomedones. It exerts anti-inflammatory activity by modulating toll-like receptor pathways and reducing neutrophil chemotaxis. It also inhibits the proliferation of Cutibacterium acnes indirectly through sebum reduction. The combination of these four actions addresses every major pathogenic factor in acne simultaneously, explaining the drug’s unique capacity to produce long-term remission.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed orally; Tmax 2–4 h; bioavailability approximately doubled with a high-fat meal | Must be taken with food; fasting administration leads to subtherapeutic levels. Lidose-isotretinoin (Absorica) has higher bioavailability regardless of food. |
| Distribution | >99.9% bound to plasma proteins (primarily albumin); highly lipophilic; distributes into skin and sebaceous glands | Detectable in semen at levels ~1 million-fold lower than an oral dose; blood donation restricted during treatment + 1 month after |
| Metabolism | Hepatic via CYP2C8, CYP2C9, CYP3A4, CYP2B6; major metabolite: 4-oxo-isotretinoin; reversible interconversion with tretinoin (all-trans-retinoic acid); further conjugation to glucuronides | Multiple active metabolites with retinoid activity; CYP involvement creates potential for drug interactions; explains need for liver function monitoring |
| Elimination | t½ isotretinoin: 10–20 h (mean ~18 h); t½ 4-oxo-isotretinoin: 24–29 h; excreted in feces and urine in approximately equal amounts; 14C-activity t½ ~90 h | Washout requires ~1 month; contraception must continue for 1 month after last dose; blood donation restricted for same period |
Side Effects
Isotretinoin produces a broad spectrum of dose-dependent adverse effects. Mucocutaneous dryness is nearly universal and is pharmacologically expected. Rates below are compiled from the FDA prescribing information, pivotal clinical trials, and large observational studies.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Cheilitis (dry, cracked lips) | ~90–100% | Dose-dependent; universally expected at 1 mg/kg/day; managed with frequent lip balm application |
| Xerosis (dry skin) | 49–70% | Dose-dependent; use fragrance-free emollients liberally; may cause retinoid dermatitis in ~20% |
| Dry eyes / Conjunctivitis | ~40% | Contact lens intolerance is common; use preservative-free artificial tears; reversible on discontinuation |
| Epistaxis | ~30–38% | Due to dry nasal mucosa; saline nasal spray and petroleum jelly applied to nasal passages helps |
| Hypertriglyceridemia | ~25% (>800 mg/dL in clinical trials) | Triglycerides elevated in up to 50% at any level; reversible on cessation; monitor fasting lipids |
| Decreased HDL cholesterol | ~15% | Reversible; contributes to transient atherogenic lipid profile during treatment |
| Elevated liver transaminases | Up to 15% | Usually mild and transient; discontinue if >5× ULN or symptomatic hepatitis develops |
| Myalgia / Arthralgia | ~16%; severe in 7.6% | Dose-related; counsel to reduce strenuous exercise; monitor CK if symptomatic |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Increased cholesterol | ~7% | Reversible; part of broader dyslipidemia effect; dietary modification may help |
| Headache | 5–10% | Usually mild; persistent severe headache with visual changes warrants urgent evaluation for pseudotumor cerebri |
| Decreased night vision | 1–5% | May persist after discontinuation in some cases; warn drivers about potential glare sensitivity |
| Skin fragility / Impaired wound healing | ~5% | Avoid waxing, dermabrasion, and ablative lasers during treatment and for 6 months after |
| Acne flare at treatment initiation | ~5–10% | More common if starting dose >0.5 mg/kg/day; may require short oral corticosteroid course if severe |
| Elevated CK | ~24% adults (≥350 U/L); 12% adolescents | More common with vigorous physical activity; half resolve within 2–4 weeks; rare cases of rhabdomyolysis (post-marketing) |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Teratogenicity (birth defects) | Extremely high risk if pregnant | Any exposure during pregnancy | ABSOLUTE CONTRAINDICATION in pregnancy; iPLEDGE REMS; 2 forms of contraception; monthly pregnancy tests |
| Pseudotumor cerebri (idiopathic intracranial hypertension) | Rare | Any time during treatment | Stop isotretinoin immediately; ophthalmology referral; avoid concomitant tetracyclines |
| Depression / Psychiatric symptoms / Suicidal ideation | Uncommon; causality debated | Any time during or after treatment | Stop isotretinoin; psychiatric evaluation; some patients may need ongoing mental health support after discontinuation |
| Acute pancreatitis (including fatal hemorrhagic) | Rare | Usually with TG >800 mg/dL | Stop isotretinoin; emergency management; do not rechallenge |
| Hepatotoxicity (severe) | Rare | Usually first 2–3 months | Discontinue if ALT >5× ULN or jaundice develops; hepatology referral |
| Skeletal effects (hyperostosis, premature epiphyseal closure, bone mineral density changes) | Uncommon with standard courses | Cumulative; more with prolonged use | Caution in adolescents with incomplete skeletal growth; baseline consideration of bone health in at-risk patients |
| Hearing impairment / Tinnitus | Rare; may persist | Variable | Discontinue isotretinoin; audiology referral; hearing loss may be irreversible in some cases |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Intolerable mucocutaneous effects | ~3–5% | Usually manageable with dose reduction and supportive care; true discontinuation uncommon |
| Lipid/liver function abnormalities | ~2–3% | Triglycerides >500 mg/dL or ALT >5× ULN requiring discontinuation; rechallenge at lower dose sometimes possible |
| Psychiatric symptoms | <2% | Depression or mood changes prompting discontinuation; causality often unclear but warrants cessation |
Mucocutaneous dryness is pharmacologically expected and often serves as a marker of therapeutic efficacy. Key management strategies include: heavy emollient use (applied immediately after bathing), lip balm with SPF applied at least 4–6 times daily, preservative-free artificial tears for dry eyes, saline nasal spray and petroleum jelly for nasal dryness, and avoidance of contact lenses during treatment if eye dryness is significant. Dose reduction rather than discontinuation should be attempted first.
Drug Interactions
Isotretinoin is metabolized by CYP2C8, CYP2C9, CYP3A4, and CYP2B6. It is highly protein-bound (>99.9%). The most critical interactions are pharmacodynamic, not pharmacokinetic.
Monitoring
Isotretinoin requires structured laboratory and clinical monitoring throughout treatment. The iPLEDGE REMS imposes additional mandatory requirements for pregnancy prevention.
- Pregnancy TestBefore, monthly, and 1 month after
RoutineTwo negative pregnancy tests before starting (CLIA-certified). Monthly pregnancy tests during treatment. One final test 1 month after stopping. Pretreatment tests must be done in a medical setting; during treatment, at-home tests may be permitted per prescriber discretion (per 2026 iPLEDGE modifications). - Fasting Lipid PanelBaseline, then every 2–4 weeks until stable
RoutineTriglycerides >500 mg/dL require dose reduction or discontinuation due to pancreatitis risk. Approximately 25% of patients develop marked triglyceride elevation (>800 mg/dL). All lipid changes are reversible on cessation. - Liver Function Tests (ALT, AST)Baseline, then every 2–4 weeks until stable
RoutineDiscontinue if transaminases exceed 5× ULN or jaundice develops. Elevations up to 15% of patients, usually mild and transient. Consensus supports checking at baseline and at peak dose. - CBCBaseline
RoutineBaseline complete blood count; repeat only if clinically indicated. Leukopenia and thrombocytopenia reported rarely. Increased ESR is common but not clinically significant. - Fasting GlucoseBaseline
RoutineIsotretinoin may rarely affect glucose metabolism. Particularly important in patients with diabetes or metabolic syndrome given concurrent dyslipidemia risk. - Psychiatric ScreeningBaseline and every visit
RoutineAsk about depression, mood changes, suicidal ideation, psychosis, and aggression at every visit. Involve family members. Isotretinoin is on the FDA’s top 10 list of drugs associated with depression reports. - Visual SymptomsEvery visit
Trigger-BasedAssess for decreased night vision, visual disturbances, and severe headache. Persistent visual changes may indicate pseudotumor cerebri or corneal opacities requiring ophthalmology referral. - Musculoskeletal SymptomsEvery visit
Trigger-BasedAsk about myalgia, arthralgia, and back pain. Check CK if symptoms are significant, especially in athletes. Consider discontinuation if significant bone or joint abnormality found.
Contraindications & Cautions
Absolute Contraindications
- Pregnancy — Known human teratogen. Isotretinoin causes a characteristic pattern of birth defects including craniofacial, cardiac, thymic, and CNS malformations. There is an extremely high risk of life-threatening birth defects with any exposure during pregnancy, even for short periods.
- Hypersensitivity to isotretinoin or any component, including parabens (used as preservatives in some capsule formulations).
- Patients not registered in iPLEDGE — Isotretinoin cannot be prescribed or dispensed outside the iPLEDGE REMS restricted distribution program.
Relative Contraindications (Specialist Input Recommended)
- Breastfeeding — Excretion in human milk is unknown; the potential for serious adverse effects in the nursing infant from retinoid exposure makes breastfeeding inadvisable.
- Pre-existing hypertriglyceridemia or pancreatitis history — Isotretinoin markedly elevates triglycerides; patients with baseline TG >500 mg/dL or a history of pancreatitis are at highest risk for acute pancreatitis.
- Active or history of severe depression, psychosis, or suicidal ideation — Relationship is debated, but risk-benefit discussion and close psychiatric monitoring are essential.
Use with Caution
- Adolescents with incomplete skeletal growth — Premature epiphyseal closure has been reported; weigh severity of acne against potential skeletal risks.
- Patients with predisposition to osteoporosis — Including those on chronic corticosteroids, anticonvulsants, or with anorexia nervosa.
- Patients who drive at night — Decreased night vision may occur suddenly and may persist after treatment cessation.
- Contact lens wearers — Ocular dryness may make contact lens use intolerable; temporary switch to glasses may be needed.
- Blood donors — Must not donate blood during treatment and for 1 month after discontinuation to prevent exposure of a pregnant recipient.
Isotretinoin can cause life-threatening birth defects. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking isotretinoin in any amount, even for short periods. Potentially any exposed fetus can be affected. There are no accurate means of determining whether an exposed fetus has been affected.
Isotretinoin is available only through the iPLEDGE REMS restricted distribution program. All patients (both male and female), prescribers, and pharmacies must be registered with iPLEDGE. Females of childbearing potential must use two forms of effective contraception simultaneously for at least 1 month before, during, and for 1 month after isotretinoin therapy, and must have monthly pregnancy tests. A 2026 FDA-approved modification to iPLEDGE allows at-home pregnancy tests during and after treatment if permitted by the prescriber, though pretreatment tests must still be done in a medical setting.
Patient Counselling
Purpose of Therapy
Isotretinoin is the most effective treatment for severe acne and is the only medication that can produce long-term remission. It works by dramatically shrinking the oil glands in the skin, reducing oil production, and clearing clogged pores. A typical course lasts 4–5 months. Most patients see significant improvement by 2–3 months, and up to 70% achieve lasting clearance after one course. However, isotretinoin has important side effects and risks that require careful monitoring.
How to Take
Take isotretinoin with a meal containing fat (this significantly increases absorption). Swallow capsules whole with a full glass of water. Do not crush, chew, or open capsules. If a dose is missed, skip it and take the next dose at the normal time — do not double up. Store at room temperature and protect from light.
Sources
- Accutane (isotretinoin) Capsules — Full Prescribing Information. Roche Laboratories. FDA Label (2008)Primary source for dosing (0.5–2 mg/kg/day, cumulative 120–150 mg/kg), boxed warning, adverse reaction rates (triglycerides 25%, HDL decrease 15%, cholesterol increase 7%), and iPLEDGE requirements.
- Absorica (isotretinoin) Capsules — Full Prescribing Information. Sun Pharmaceutical Industries. FDA Label (2012)Source for lidose-isotretinoin formulation data, protein binding (>99.9%), CYP metabolism pathway details, and arthralgias incidence (severe in 7.6%).
- Isotretinoin Capsules USP (Zenatane) — Full Prescribing Information. DailyMed. DailyMedCurrent generic isotretinoin labeling with updated iPLEDGE language and pregnancy/lactation guidance.
- Strauss JS, Leyden JJ, Lucky AW, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial. J Am Acad Dermatol. 2001;45(2):196-207. PubMed: 11464180Multicenter RCT (N=600) providing cheilitis prevalence of 90.3% (conventional) and 91.3% (micronized isotretinoin), establishing near-universal mucocutaneous dryness.
- Blasiak RC, Stamey CR, Burkhart CN, et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013;149(12):1392-1398. PubMed: 24173260Demonstrated that higher cumulative doses reduce relapse rates; cheilitis and xerosis were nearly universal regardless of dosing group.
- Del Rosso JQ. Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses. J Clin Aesthet Dermatol. 2012;5(11):17-24. PubMed: 23198008Comprehensive review of isotretinoin dosing strategies, relapse predictors, and the rationale for the 120–150 mg/kg cumulative dose target.
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. DOI: 10.1016/j.jaad.2015.12.037AAD evidence-based guideline recommending isotretinoin for severe acne and patients with scarring risk or psychosocial burden; endorses 120–150 mg/kg cumulative dose.
- Goldsmith LA, Bolognia JL, Callen JP, et al. American Academy of Dermatology consensus conference on the safe and optimal use of isotretinoin. J Am Acad Dermatol. 2004;50(6):900-906. PubMed: 15153893AAD consensus on monitoring requirements, pregnancy prevention, and psychiatric risk assessment during isotretinoin therapy.
- Nelson AM, Zhao W, Gilliland KL, et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Invest. 2008;118(4):1468-1478. DOI: 10.1172/JCI33869Landmark study identifying NGAL as a key mediator of isotretinoin-induced sebocyte apoptosis, explaining the drug’s unique sebosuppressive mechanism.
- Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol. 2012;132(9):2198-2205. PubMed: 22513780Demonstrates isotretinoin’s anti-inflammatory mechanism via toll-like receptor 2 pathway normalization in acne-prone skin.
- Colburn WA, Vane FM, Shorter HJ. Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man. Eur J Clin Pharmacol. 1983;24(5):689-694. DOI: 10.1007/BF00542224Foundational PK study establishing isotretinoin elimination half-life of ~17.4 h and metabolite (4-oxo) kinetics in healthy subjects.
- Lucek RW, Colburn WA. Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet. 1985;10(1):38-62. PubMed: 3882304Comprehensive PK review comparing isotretinoin and etretinate; establishes t½ range of 10–20 h for isotretinoin and 24–29 h for its 4-oxo metabolite.
- Kapała J, Lewandowska J. Adverse events in isotretinoin therapy: a single-arm meta-analysis. Pharmaceuticals (Basel). 2022;15(6):716. DOI: 10.3390/ph15060716Meta-analysis of 30 clinical trials establishing pooled incidence of xerosis (49%), cheilitis (41%), and retinoid dermatitis (27%) across isotretinoin formulations.